Sunshine Biopharma, Inc. (SBFMW)
- Previous Close
0.1511 - Open
0.1800 - Bid --
- Ask --
- Day's Range
0.1300 - 0.1864 - 52 Week Range
0.1300 - 0.1864 - Volume
18,863 - Avg. Volume
-- - Market Cap (intraday)
-- - Beta (5Y Monthly) -0.78
- PE Ratio (TTM)
-- - EPS (TTM)
-2.2140 - Earnings Date --
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
--
Sunshine Biopharma, Inc., a pharmaceutical company, focuses on the research and development of life-saving medicines in various therapeutic areas, including oncology and antivirals in the United States and Canada. It operates in two segments, Prescription Generic Pharmaceuticals and Nonprescription Over-The-Counter Products. The company is developing SBFM-PL4, a protease inhibitor for the treatment of SARS coronavirus infections; Adva-27a, a small chemotherapy molecule to treat pancreatic cancer; and K1.1 mRNA, a lipid nano-particle for liver cancer. It also offers Essential 9, an amino acids capsules; Calcium-Vitamin D supplement under the Essential Calcium-Vitamin D brand name; and L-Citrulline and Taurine products. In addition, the company provides various generic prescription drugs for osteoporosis, cardiovascular, antipsychotic, antibacterial, hypertension, anti-inflammatory, allergy, antibiotic, central nervous system, diabetes, urology, antifungal, antimalarial, oncology, gastroenterology, and anticonvulsant indications. Sunshine Biopharma, Inc. is headquartered in New York, New York.
sunshinebiopharma.com44
Full Time Employees
--
Fiscal Year Ends
Sector
Recent News: SBFMW
Compare To: SBFMW
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: SBFMW
Valuation Measures
Market Cap
--
Enterprise Value
--
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
--
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
-18.70%
Return on Assets (ttm)
-10.57%
Return on Equity (ttm)
-21.04%
Revenue (ttm)
24.09M
Net Income Avi to Common (ttm)
-4.51M
Diluted EPS (ttm)
-2.2140
Balance Sheet and Cash Flow
Total Cash (mrq)
16.29M
Total Debt/Equity (mrq)
3.10%
Levered Free Cash Flow (ttm)
-8.2M
Research Analysis: SBFMW
Company Insights: SBFMW
SBFMW does not have Company Insights